在线 一区二区三区 国产,5060午夜看片在线观看,在线观看中文字幕日本一区

About Us

Global

R&D

Investor Relations

About Us

Leading the pharmaceutical industry to become a superior provider of pharmaceutical products and services.

1993 Year
Founded in 1993
2000 +
There are more than 2083 pharmaceutical R&D personnel
70 +
Export to 70 countries and regions
500 +
The group is developing 500 products
820 +
822 patents granted
1993 Year
Founded in 1993
2000 +
There are more than 2083 pharmaceutical R&D personnel
70 +
Export to 70 countries and regions
500 +
The group is developing 500 products
820 +
822 patents granted
Global

Adhere to R&D innovation and international expansion.

EPIC Pharma

St. Louis Research and Development Center

PuraCap Pharmaceutical

Humanwell Pharma Mali

Humanwell Pharma Afrique

Humanwell Pharmaceutical Ethiopia

YiChang Humanwell Pharmaceutical

Humanwell Puracap Phamaceuticals (Wuhan)

Likang Pharmaceutical

Paion Pharma

Paion UK

Xinjiang Xipa Pharmaceutical

EPIC Pharma

Having the qualifications for the production and operation of controlled drugs and holding over 60 ANDA approvals; Having a mature sales network in the US market; A CMO site recognized by multinational pharmaceutical companies for a long time.

St. Louis Research and Development Center

The company's important strategic layout for promoting internationalization includes cutting-edge information research, new drug discovery and exploration, high-end formulation research and industrialization, and coordinated development with the international registration, production, export, and independent marketing of the company's products. Focusing on strategic areas such as anesthesia, analgesia, and central nervous system diseases, there are products under research in innovative drugs, high-end sustained-release formulations, and complex injection formulations.

PuraCap Pharmaceutical

PuraCap Pharmaceuticals LLC, established in 2008 in New Jersey, is among the earliest Chineses-backed pharmaceutical companies in the USA. The company is engaged in the market entry and distribution of OTC products in the US, and its specialty products are soft gel capsules.

Humanwell Pharma Mali

Commercial pharmaceutical company covering eight French speaking regions in West Africa

Humanwell Pharma Afrique

The first modern pharmaceutical factory in West Africa, ending the history of Mali being unable to produce drugs; Production of injectable, oral solid/liquid and other preparations

Humanwell Pharmaceutical Ethiopia

Modern pharmaceutical factories in Ethiopia; the first pharmaceutical factory invested in and constructed by a Hubei enterprise in Ethiopia; production of oral solid/liquid formulations and small volume injections.

YiChang Humanwell Pharmaceutical

The first oral solid dosage form factory in Hubei Province to be certified by the US FDA and the UK MHRA; Focus on the research and development, registration, production, and international sales of sustained-release oral solid preparations and transdermal generic drugs that meet national standards.

Humanwell Puracap Phamaceuticals (Wuhan)

The first soft capsule production enterprise in Hubei Province to pass the US FDA certification; Leading supplier of soft capsule drug formulations in the US market; A leading enterprise in the research and production of global soft capsule drug formulations.

Likang Pharmaceutical

Having dual qualifications from NMPA and FDA, covering injections and high-end oral solid preparations, we undertake the entire process of clinical sample to commercial production commissioning business.

Paion Pharma

Headquartered in Aachen of Germany, the company focuses on the R&D and commercialization of innovative pharmaceutical products for anesthesia and critical care.

Xinjiang Xipa Pharmaceutical

The company established a subsidiary in the Republic of Uzbekistan in 2016, and established a professional marketing academic promotion team and registration team. The company has registered six kinds of Uyghur medicines, and the sales scope covers the entire territory of Uzbekistan.

Continue to build and improve the high-end technology platform, and promote the technology transfer and introduction of new products through industry-university-research cooperation.

More than 500 products under development, projects and more than 60 new drugs of category 1 and 2 under development

822 authorized patents, 407 invention patents, and 74 overseas authorized patents

Covering Europe, the United States, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, Taiwan, China and other countries and regions


Continuously building and improving high-end technology platforms, promoting technology transfer and introduction of new products through industry university research cooperation

While building a first-class R&D innovation platform, we provide comprehensive services for new drug research, development, clinical trials, and registration


We have a research team centered around overseas pharmaceutical experts, domestic pharmaceutical PhDs, and master’s degree holders

There are over 2,000 R&D personnel, including more than 120 PhDs, and 9 experts who enjoy special allowances from the State Council

Investor Relations
Periodical Ad-hoc
Explore more Explore more
北宁市 大同市 长岭县 巴楚县 靖边县 沧源
普定县 昭通市 乌兰县 舟曲县 连州市 定兴县
阳西县 凤山县 黑河市 聊城市 会泽县 乌拉特中旗
泛站蜘蛛池模板: 屯门区| 丹东市| 嵩明县| 南雄市| 裕民县| 揭阳市| 天全县| 三门峡市| 岳阳县| 连城县| 阿克苏市| 栾城县| 兴义市| 穆棱市| 宜川县| 泰兴市| 南涧| 衡阳县| 屏东县| 赣州市| 渝中区| 外汇| 新沂市| 武宣县| 弥渡县| 拜城县| 元氏县| 富民县| 内乡县| 云南省| 台江县| 来宾市| 洞头县| 临夏县| 聂荣县| 泰兴市| 巩义市| 东乌| 崇仁县| 鸡东县| 广州市|